The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Salix Pharmaceuticals Ltd

Nasdaq: SLXP
Last

(U.S.) $117.20

Today's change-1.25 -1.06%
Updated December 19 4:00 PM EST. Delayed by at least 15 minutes.
 

Salix Pharmaceuticals Ltd

Nasdaq: SLXP
Last

(U.S.) $117.20

Today's change-1.25 -1.06%
Updated December 19 4:00 PM EST. Delayed by at least 15 minutes.

Salix Pharmaceuticals Ltd down (U.S.)$1.25

Salix Pharmaceuticals Ltd closed lower Friday, dropping (U.S.)$1.25 or 1.06% to (U.S.)$117.20. Over the last five days, shares have gained 13.39% and 30.31% year to date. Shares have outperformed the S&P 500 by 22.54% during the last year.

Key company metrics

  • Open(U.S.) $118.54
  • Previous close(U.S.) $118.45
  • High(U.S.) $120.42
  • Low(U.S.) $116.46
  • Bid / Ask-- / --
  • YTD % change+30.31%
  • Volume2,266,597
  • Average volume (10-day)1,846,964
  • Average volume (1-month)1,943,186
  • Average volume (3-month)2,712,329
  • 52-week range(U.S.) $84.10 to (U.S.) $172.98
  • Beta0.87
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forward28.67×
  • Forward PEG1.78×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.27
Updated December 19 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-5.58%

Salix Pharmaceuticals Ltd has a net profit margin of -5.58%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.85%Sector:HealthcareIndustry:Pharmaceuticals - Generic & Specialty
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue355382384258
Total other revenue--------
Total revenue355382384258
Gross profit268278269201
Total cost of revenue8610411657
Total operating expense434334422162
Selling / general / administrative16612519580
Research & development51395336
Depreciation / amortization55555511
Interest expense (income), net operating--------
Unusual expense (income)77104-23
Other operating expenses, total--------
Operating income-8048-3896
Interest income (expense), net non-operating-44-42-42-15
Gain (loss) on sale of assets--------
Other--------
Income before tax-1256-8081
Income after tax-893-4452
Income tax, total-363-3629
Net income-893-4452
Total adjustments to net income--------
Net income before extra. items-893-4452
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-893-4452
Inc. avail. to common incl. extra. items-893-4452
Diluted net income-893-4452
Dilution adjustment000--
Diluted weighted average shares64756368
Diluted EPS excluding extraordinary itemsvalue per share-1.390.04-0.690.77
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.610.12-0.650.55